Dr. Ami U. Badami, M.D.
Medical Oncology (Medical Oncology Physician)
2650 Ridge Ave
Evanston, IL 60201
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 206
Licensed in Illinois since 2016, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036140250 (first issued 2016; active) -
Hematology & Oncology Physician
IL license 036140250 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northshore University Healthsystem - Evanston Hospital Evanston, IL
- Swedish Hospital Chicago, IL
- Loyola University Medical Center Maywood, IL
Medical groups
- Endeavor Health Medical Group (3,350 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 206
- Services billed
- 635
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 486 | 189 |
| Established patient office or other outpatient visit, 40-54 minutes | 247 | 95 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 88 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 55 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 50 | 50 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 21 |
| Hospital discharge day management, more than 30 minutes | 19 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 160 |
| Prednisone Other prescribers in Evanston, IL | 85 |
| Xtandi (enzalutamide) | 72 |
| Nubeqa (darolutamide) | 38 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Evanston, IL | 34 |
| Erleada (apalutamide) | 31 |
| Ondansetron Hcl Other prescribers in Evanston, IL | 25 |
| Prochlorperazine Maleate Other prescribers in Evanston, IL | 24 |
| Tramadol Hcl Other prescribers in Evanston, IL | 21 |
| Gabapentin Other prescribers in Evanston, IL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 8 payments worth $213 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $51.29 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $50.76 |
| Abbott Laboratories | $36.20 |
| Tempus Ai, Inc | $28.47 |
| Merck Sharp & Dohme LLC | $25.70 |
| EMD Serono, Inc. | $20.13 |
| Food and Beverage | $187 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC May 2, 2025 | Education WELIREG · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $39,293 in research payments for these studies, mostly to the institutions running them.
- A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.